Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

44.76 USD -13.49 (-23.16%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 4, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,859,869
Open 53.50
Bid (Size) 44.02 (1)
Ask (Size) 44.97 (1)
Prev. Close 58.25
Today's Range 42.16 - 53.98
52wk Range 24.87 - 129.71
Shares Outstanding 26,320,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Stud
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and... 
From Business Wire News Releases
Vingroup collaborates with Arcturus Therapeutics to establish a manufacturing facility in Vietnam for Arcturus’ mRNA Covid-19 vaccine
From News Direct

Performance

YTD
-8.47%
-8.47%
1 Month
+30.84%
+30.84%
3 Month
+34.37%
+34.37%
6 Month
-43.01%
-43.01%
1 Year
-17.08%
-17.08%

More News

Read More
Mid-Afternoon Market Update: Dow Jumps Over 200 Points; Neuronetics Shares Plunge
Tags MOHO Small Cap WHLM
From Benzinga
Understanding Arcturus Therapeutics's Unusual Options Activity
Tags Market News Movers Benzinga
From Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Tags Markets Market News ARCT
From Benzinga
Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher
Tags BABA News Eurozone
From Benzinga
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
From Business Wire News Releases
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
From Business Wire News Releases
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
From Business Wire News Releases
Noteworthy Monday Option Activity: CLX, ARCT, ADBE
Tags Stocks
From Market News Video
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
Tags Options TVTX Market News
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.